Bio-Rad Laboratories anti-idiotypic antibodies and Human IgM-FcSpyCatcher reagent

Bio-Rad Laboratories has extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to pertuzumab (Perjeta), guselkumab (Tremfya), canakinumab (Ilaris), belimumab (Benlysta) and the bispecific drug emicizumab (Hemlibra). The company has also extended its range of SpyCatcher reagents to include Human IgM-FcSpyCatcher.

Bio-Rad’s comprehensive range of anti-biotherapeutic antibodies enables the development of robust bioanalytical assays against biologic drugs and is suitable for use in pharmacokinetic (PK) and anti-drug-antibody (ADA) assays for pertuzumab, guselkumab, canakinumab, belimumab and emicizumab, facilitating therapeutic drug monitoring for innovator and biosimilar products.

Human IgM-FcSpyCatcher is a reagent that allows researchers to rapidly switch antibody formats at the protein level, enabling spontaneous formation of pentameric and hexameric IgMs. Compatible with the company’s recombinant HuCAL antibodies, the reagent has been successfully tested in ELISA, western blotting and precipitation assays.

The company’s antibodies and reagents are approved for in vitro research, with the anti-idiotypic antibodies also approved for commercial in vitro testing services to support preclinical and clinical drug and biosimilar development, and patient monitoring.